Showing results (1-10 of 211) with videos related to
Sort By:
Pageof 22
Critical Reviews in Oncology/Hematology|June 6, 2016
Early switch in tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia: An emerging clinical questionKendra Sweet, Javier Pinilla-IbarzBest Practice & Research. Clinical Haematology|November 15, 2016
NCCN and ELN: What do the guidelines tell us?Kendra Sweet, Javier Pinilla-IbarzPatient Preference and Adherence|July 22, 2014
Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerationsKendra Sweet, Javier Pinilla-Ibarz, Ling ZhangJournal of Hematology & Oncology|July 23, 2013
Biomarkers for determining the prognosis in chronic myelogenous leukemiaKendra Sweet, Ling Zhang, Javier Pinilla-IbarzAnticancer Research|December 6, 2015
Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid LeukemiaJavier Pinilla-Ibarz, Kendra Sweet, Josephine Emole, et al.Expert Review of Hematology|March 12, 2019
Can increased immunogenicity in chronic myeloid leukemia improve outcomes?Onyee Chan, Chetasi Talati, Kendra Sweet, et al.Blood Advances|February 12, 2020
Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemiaOnyee Chan, Chetasi Talati, Leidy Isenalumhe, et al.Leukemia Research|October 20, 2018
A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of diseaseKendra Sweet, Lori Hazlehurst, Eva Sahakian, et al.Current Hematologic Malignancy Reports|October 2, 2021
BTK Inhibitors in Chronic Lymphocytic LeukemiaSameh Gaballa, Javier Pinilla-IbarzCurrent Oncology Reports|August 19, 2008
Modern approaches to treating chronic myelogenous leukemiaJavier Pinilla-Ibarz, Celeste BelloPageof 22